Use of a water-impermeable, friction-reducing barrier film (BF) may reduce skin toxicity (eg, radiation dermatitis, burning, and pruritus) on high-friction breast regions in women with breast cancer receiving post-lumpectomy adjuvant radiation therapy, according to a study.
Measuring the ratio of the soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) improves the accuracy of identifying pre-eclampsia without changing admission rates, according to the results of a trial.
Patients with HER2+ breast cancer with disease progression despite ≥2 lines of HER2-directed therapy may improve their progression-free survival (PFS) with the addition of neratinib than lapatinib to capecitabine, according to the phase III NALA* trial.
Infection with hepatitis B virus (HBV) does not appear to independently affect pregnancy outcomes, although it contributes to prolonged infertility, higher odds of secondary infertility, ovulatory disorders and reduced implantation rate, a study has found.
Consuming polyphenol-rich pomegranate juice during pregnancy was associated with better microstructural development and functional connectivity in the brains of newborns with intrauterine growth restriction (IUGR), suggests preliminary evidence from a pilot randomized study.
Pregnancy attenuates the risk of endometrial cancer regardless of whether it ends shortly after conception or at 40 weeks of gestation, a study has shown. A biological process occurring within the first weeks of pregnancy drives this risk reduction, as shown by pregnancies terminated through induced abortions having similar risk reductions as those ending in childbirth.
Treatment with the selective PARP* 1/2 inhibitor niraparib after a response to first-line platinum-based chemotherapy significantly extends progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer, including those at high risk of relapse, according to the PRIMA** study presented at ESMO 2019.